IL158615A0 - Modified factor vii in treatment of acute lung injury or acute respiratory distress syndrome - Google Patents

Modified factor vii in treatment of acute lung injury or acute respiratory distress syndrome

Info

Publication number
IL158615A0
IL158615A0 IL15861502A IL15861502A IL158615A0 IL 158615 A0 IL158615 A0 IL 158615A0 IL 15861502 A IL15861502 A IL 15861502A IL 15861502 A IL15861502 A IL 15861502A IL 158615 A0 IL158615 A0 IL 158615A0
Authority
IL
Israel
Prior art keywords
acute
treatment
factor vii
respiratory distress
distress syndrome
Prior art date
Application number
IL15861502A
Other languages
English (en)
Original Assignee
Novo Nordisk As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novo Nordisk As filed Critical Novo Nordisk As
Publication of IL158615A0 publication Critical patent/IL158615A0/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/36—Blood coagulation or fibrinolysis factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A61K38/4846—Factor VII (3.4.21.21); Factor IX (3.4.21.22); Factor Xa (3.4.21.6); Factor XI (3.4.21.27); Factor XII (3.4.21.38)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Cardiology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pulmonology (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Zoology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
IL15861502A 2001-05-02 2002-05-01 Modified factor vii in treatment of acute lung injury or acute respiratory distress syndrome IL158615A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DKPA200100692 2001-05-02
PCT/DK2002/000279 WO2002087605A2 (en) 2001-05-02 2002-05-01 Modified fvii in treatment of ards

Publications (1)

Publication Number Publication Date
IL158615A0 true IL158615A0 (en) 2004-05-12

Family

ID=8160467

Family Applications (1)

Application Number Title Priority Date Filing Date
IL15861502A IL158615A0 (en) 2001-05-02 2002-05-01 Modified factor vii in treatment of acute lung injury or acute respiratory distress syndrome

Country Status (12)

Country Link
US (1) US20040033200A1 (xx)
EP (1) EP1385535A2 (xx)
JP (1) JP2004527554A (xx)
KR (1) KR20040094288A (xx)
CN (1) CN1522151A (xx)
AU (1) AU2002338487A1 (xx)
CA (1) CA2445811A1 (xx)
HU (1) HUP0304050A3 (xx)
IL (1) IL158615A0 (xx)
PL (1) PL366564A1 (xx)
RU (1) RU2003134701A (xx)
WO (1) WO2002087605A2 (xx)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060235209A9 (en) * 1997-03-10 2006-10-19 Jin-An Jiao Use of anti-tissue factor antibodies for treating thromboses
US20030109680A1 (en) * 2001-11-21 2003-06-12 Sunol Molecular Corporation Antibodies for inhibiting blood coagulation and methods of use thereof
WO2001005353A2 (en) 1999-07-14 2001-01-25 Novo Nordisk A/S USE OF FVIIa OR A TISSUE FACTOR ANTAGONIST FOR REGULATING GENE EXPRESSION AND CELL MIGRATION OR CHEMOTAXIS
ES2527102T3 (es) * 2003-06-19 2015-01-20 Genentech, Inc. Composiciones y métodos para el tratamiento de trastornos relacionados con la coagulación
ES2381110T3 (es) 2003-09-09 2012-05-23 Novo Nordisk Health Care Ag Polipéptidos de factor VII de coagulación
EP1799243B1 (en) * 2004-10-06 2015-07-15 University Of Rochester Treatment of pulmonary hypertension using an agent that inhibits a tissue factor pathway
AU2006273696B2 (en) * 2005-06-24 2012-08-30 Drugrecure Aps Airway administration of activated protein C in inflammatory conditions affecting the respiratory tract
US20110142837A1 (en) * 2007-07-20 2011-06-16 Trustees Of The University Of Pennsylvania Method Of Treating Acute Respiratory Distress Syndrome
US8251876B2 (en) * 2008-04-22 2012-08-28 Hill-Rom Services, Inc. Breathing exercise apparatus
US9180271B2 (en) 2012-03-05 2015-11-10 Hill-Rom Services Pte. Ltd. Respiratory therapy device having standard and oscillatory PEP with nebulizer

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5997864A (en) * 1995-06-07 1999-12-07 Novo Nordisk A/S Modified factor VII
US5833982A (en) * 1991-02-28 1998-11-10 Zymogenetics, Inc. Modified factor VII
DE69233398D1 (de) * 1991-02-28 2004-09-16 Novo Nordisk As Modifizierter faktor-vii
DE60014919T2 (de) * 1999-08-06 2005-10-13 Genentech, Inc., South San Francisco Peptidantagonisten des faktors viia
BR0215218A (pt) * 2001-12-21 2004-11-16 Novo Nordisk As Composição aquosa lìquida, método para a preparação da mesma, uso de uma composição, e, métodos para a inibição da coagulação do sangue em um indivìduo, e inibição de reações mediadas pelo fator de tecido em um indivìduo

Also Published As

Publication number Publication date
CN1522151A (zh) 2004-08-18
KR20040094288A (ko) 2004-11-09
HUP0304050A2 (hu) 2004-03-29
WO2002087605A2 (en) 2002-11-07
RU2003134701A (ru) 2005-03-27
US20040033200A1 (en) 2004-02-19
WO2002087605A3 (en) 2003-01-03
HUP0304050A3 (en) 2005-12-28
AU2002338487A1 (en) 2002-11-11
CA2445811A1 (en) 2002-11-07
EP1385535A2 (en) 2004-02-04
PL366564A1 (en) 2005-02-07
JP2004527554A (ja) 2004-09-09

Similar Documents

Publication Publication Date Title
EP1699514A4 (en) MECHANICAL VENTILATION FOR BREATHING IN SLEEP
AU4579401A (en) Lung treatment apparatus
AU2003264282A1 (en) Phenethanolamine derivatives and their use in the treatment of respiratory diseases
IL150027A0 (en) Carbon dioxide enhancement of inhalation therapy
EE200400059A (et) Diarüültsükloalküülderivaadid, nende kasutamine ravimite valmistamiseks ning neid sisaldav ravim
HK1076686A1 (en) Smoking article and use thereof
EP1701756A4 (en) MACRO CONTROL OF THE TREATMENT OF BREATHING IN SLEEP
PL387118A1 (pl) Kapsułki do inhalacji zawierające tiotropium i ich zastosowanie
HK1061212A1 (en) Pyranoindazoles and their use for the treatment ofglaucoma
SI1530466T1 (sl) Uporaba nintedaniba za zdravljenje pljučne fibroze
IL158615A0 (en) Modified factor vii in treatment of acute lung injury or acute respiratory distress syndrome
EP1624850A4 (en) COMPOSITIONS AND METHODS FOR THE TREATMENT OF SEVERE ACUTE RESPIRATORY SYNDROME (SARS)
GB0004531D0 (en) The treatment of respiratory diseases
EP1575582A4 (en) COMBINED THERAPY FOR THE TREATMENT OF ACUTE LEUKEMIA AND MYELODYSPLASIC SYNDROME
AU2003232148A8 (en) A selective inos inhibitor and a pde inhibitor in combination for the treatment of respiratory diseases
EP1448185A4 (en) TREATMENT OF ASTHMA, CHRONIC OBSTRUCTIVE LUNG DISEASES AND / OR OTHER RESPIRATORY PROBLEMS
IL164078A0 (en) Treatment of lung disorder
EE200300513A (et) Piperasinoderivaadid, nende kasutamine hingamisteede haigusnähte leevendavate ravimite valmistamiseks ning neid sisaldavad ravimid
EP1450831A4 (en) PROCESS FOR TREATMENT IN SITU IN THE LUNGS OF MAMMALS
AU2002231283A1 (en) Use of p38 inhibitors for the treatment of smoke inhalation
SI1216047T1 (sl) Kombinacija loteprednola in agonistov beta2-adrenoceptorja in njena uporaba za zdravljenje bronhialne astme
EP1389129A4 (en) METHOD FOR TREATING RESPIRATORY DISEASES
NO996060D0 (no) Pusteapparat for behandling av soevnapne
AU2003260033A1 (en) Methods of treating acute respiratory distress syndrome
DE60022070D1 (de) Verwendung von stickstoffoxid zur behandlung von atemwegs-verengungen